# Novel Biomarkers to Shorten TB Treatment

> **NIH NIH R01** · RBHS-NEW JERSEY MEDICAL SCHOOL · 2020 · $659,830

## Abstract

ABSTRACT
The current recommended treatment duration for pulmonary tuberculosis (TB) is six months. Despite this
recommendation, approximately 5% of TB patients will fail treatment and an additional 5% will relapse. While
failure and relapse patients might well have been cured with longer or more intensive therapy, many patients
can clearly be treated successfully in four months or less. Identifying markers that could assign patients to
shorter or longer therapy could transform TB treatment, improving outcomes, increasing adherence and
decreasing costs. This proposal will identify biomarkers that predict response to four and six month TB
treatment. We found that the number of M. tuberculosis genomes (genome load) present in sputum at the start
of treatment, and the rate of genome load decline with treatment, is predictive of treatment outcome. We have
also shown that even in subjects with fully drug-susceptible M. tuberculosis (as defined by standard
breakpoints), considerable heterogeneity among the minimal inhibitory concentrations (MICs) of each isolate
remains. Importantly, we found that MIC correlated very strongly with treatment outcome, even controlling for
clinical characteristics. Although our novel biomarkers appear to be highly prognostic, host drug absorption-
distribution (pharmacokinetics, PK) is also likely to be of prognostic value, especially as PK interacts with MIC
at the patient level. We will test, improve and validate each of our novel treatment response markers using
samples obtained from TB patients enrolled into the joint Tuberculosis Trials Consortium and AIDS Clinical
Trial Group study 31/A5349, treated for four or six months and followed 18 months for relapse. We will create
the first comprehensive predictive model of TB treatment response and cure incorporating genome load, pre-
treatment MIC and host PK, and identify genomic and transcriptional markers that can replace bacterial MIC
with a rapid pre-treatment test. This will be done in the following three aims: 1) Test and refine molecular
measures of (a) initial bacterial load and (b) change in bacterial load (as measured by the slope) in response to
therapy, as predictors of successful four and six month treatment for drug-susceptible TB. 2) Investigate the
contribution of bacterial sub-breakpoint MICs as a predictor of successful four and six month treatment for
drug-susceptible TB; and identify simplified markers (new critical MIC values, and mRNA or mutations in the
bacterial chromosome) with the potential to be developed into a predictive test. 3) Develop and test a highly
predictive algorithm that identifies TB patients who will be cured with short course (i.e. ≤ 4 months) TB
treatment, in a model that includes measurable clinical characteristics, host pharmacokinetics (PK), and the
measures refined and validated individually in aims 1 and 2.

## Key facts

- **NIH application ID:** 9926212
- **Project number:** 5R01AI126788-05
- **Recipient organization:** RBHS-NEW JERSEY MEDICAL SCHOOL
- **Principal Investigator:** David Alland
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $659,830
- **Award type:** 5
- **Project period:** 2016-06-22 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9926212

## Citation

> US National Institutes of Health, RePORTER application 9926212, Novel Biomarkers to Shorten TB Treatment (5R01AI126788-05). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/9926212. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*